Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.
Cleveland BioLabs, Inc. (NASDAQ: CBLI) shares declined 8.01 percent to close at $0.69 a share Friday. The stock traded between $0.68 and $0.75 on volume of 2.36 million shares traded. Analysts at Cantor Fitzgerald have recently downgraded the company’s rating to "hold" from "buy". Shares of Cleveland BioLabs have fallen approximately 50.0 percent year to-date.
Find out more about Cleveland BioLabs including full access to the free equity report at:
Corrections Corp of America (NYSE: CXW) shares declined 2.57 percent to close at $33.73 a share Friday. The stock traded between $33.72 and $34.32 on volume of 822,094 shares traded. Analysts at CRT Capital have recently initiated coverage on the company with a "fair value" rating. Shares of Corrections Corp of America have fallen approximately 10.0 percent in the past year.
Find out more about Corrections Corp of America including full access to the free equity report at:
Maxim Integrated Products Inc. (NASDAQ: MXIM) shares increased 1.11 percent to close at $29.20 a share Friday. The stock traded between $29.01 and $30.20 on volume of 6.75 million shares traded. Analysts at Susquehanna have recently upgraded the company’s rating to "positive" from "neutral". Shares of Maxim Integrated Products have fallen approximately 4.0 percent in the past year.
Find out more about Maxim Integrated Products including full access to the free equity report at:
Protalix BioTherapeutics Inc. (NYSEMKT: PLX) shares declined 1.11 percent to close at $4.47 a share Friday. The stock traded between $4.26 and $4.51 on volume of 325,929 shares traded. Analysts at R. F. Lafferty have recently initiated coverage on the company with a "buy" rating. Shares of Protalix BioTherapeutics have fallen approximately 14.0 percent in the past year.
Find out more about Protalix BioTherapeutics including full access to the free equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.
Research Driven Investing